{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:34:14Z","timestamp":1793039654906,"version":"4.5.0"},"reference-count":78,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal dystrophies characterized by progressive photoreceptor degeneration and vision loss. While current management is largely supportive\u2014relying on visual aids, orientation training, and nutritional supplementation\u2014these interventions offer only symptomatic relief and do not halt disease progression. Advances in molecular genetics have led to the development of targeted treatments, including gene replacement therapy, RNA-based therapies, and CRISPR\/Cas9 gene editing, offering promising strategies for disease modification. The approval of voretigene neparvovec for RPE65-associated RP marked a milestone in gene therapy, while ongoing trials targeting mutations in RPGR, USH2A, and CEP290 are expanding therapeutic options. Optogenetic therapy and stem cell transplantation represent additional strategies, particularly for patients with advanced disease. Challenges persist in delivery efficiency, immune responses, and treating large or dominant-negative mutations. Non-viral vectors, nanoparticle systems, and artificial intelligence-guided diagnostics are being explored to address these limitations and support personalized care. This review summarizes the current and emerging therapeutic landscape for RP, highlighting the shift toward precision medicine and the need for continued innovation to overcome genetic and phenotypic variability.<\/jats:p>","DOI":"10.3390\/medicina61071179","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T03:54:28Z","timestamp":1751255668000},"page":"1179","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Retinitis Pigmentosa: From Genetic Insights to Innovative Therapeutic Approaches\u2014A Literature Review"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2610-4019","authenticated-orcid":false,"given":"Ricardo A.","family":"Murati Calder\u00f3n","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, University of Puerto Rico, San Juan 00936-5067, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Emanuelli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, University of Puerto Rico, San Juan 00936-5067, Puerto Rico"},{"name":"Emanuelli Research and Development, Retina Care, Arecibo 00612-4368, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalio","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Puerto Rico, Medical Sciences Campus, San Juan 00936-5067, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","article-title":"Non-syndromic retinitis pigmentosa","volume":"66","author":"Verbakel","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_2","first-page":"223","article-title":"Population Genetic Studies of Retinitis Pigmentosa","volume":"32","author":"Boughman","year":"1980","journal-title":"Am. J. Hum. Genet."},{"key":"ref_3","unstructured":"Hartong, D.T., Berson, E.L., and Dryja, T.P. (2025, February 03). Retinitis Pigmentosa Prevalence and Inheritance Patterns, Available online: www.ncbi.nlm.nih.gov\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Birtel, J., Gliem, M., Mangold, E., M\u00fcller, P.L., Holz, F.G., Neuhaus, C., Lenzner, S., Zahnleiter, D., Betz, C., and Eisenberger, T. (2018). Next-generation sequencing identifies unexpected genotype-phenotype correlations in patients with retinitis pigmentosa. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207958"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/archopht.125.2.151","article-title":"Perspective on Genes and Mutations Causing Retinitis Pigmentosa","volume":"125","author":"Daiger","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1167\/iovs.08-2009","article-title":"Disease course in patients with autosomal recessive retinitis pigmentosa due to the USH2A Gene","volume":"49","author":"Sandberg","year":"2008","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-019-1250-7","article-title":"Novel mutations of RPGR in Chinese families with X-linked retinitis pigmentosa","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Liu, W., Liu, S., Li, P., and Yao, K. (2022). Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094883"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archopht.1993.01090060049022","article-title":"A Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa","volume":"111","author":"Berson","year":"1993","journal-title":"Arch. Ophthalmol."},{"key":"ref_10","first-page":"687","article-title":"Visual Rehabilitation in Patients with Retinitis Pigmentosa","volume":"69","author":"Berezovsky","year":"2006","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Colombo, L., Baldesi, J., Martella, S., Quisisana, C., Antico, A., Mapelli, L., Montagner, S., Primon, A., and Rossetti, L. (2025). Managing Retinitis Pigmentosa: A Literature Review of Current Non-Surgical Approaches. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020330"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2017.10.004","article-title":"Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives","volume":"63","author":"Dias","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.ophtha.2016.06.041","article-title":"Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New Frontier","volume":"123","author":"MacLaren","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/eye.2016.197","article-title":"A challenge to the striking genotypic heterogeneity of retinitis pigmentosa: A better understanding of the pathophysiology using the newest genetic strategies","volume":"30","author":"Sorrentino","year":"2016","journal-title":"Eye"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12413","DOI":"10.1073\/pnas.0503460102","article-title":"RPE65 is the isomerohydrolase in the retinoid visual cycle","volume":"102","author":"Moiseyev","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1167\/iovs.12-10070","article-title":"RPGR-associated retinal degeneration in human X-linked RP and a murine model","volume":"53","author":"Huang","year":"2012","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41467-023-36431-1","article-title":"The usherin mutation c.2299delG leads to its mislocalization and disrupts interactions with whirlin and VLGR1","volume":"14","author":"Tebbe","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.10.002","article-title":"The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy","volume":"62","author":"Athanasiou","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/978-3-031-27681-1_65","article-title":"Redox Status in Retinitis Pigmentosa","volume":"Volume 1415","author":"Velasco","year":"2023","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.preteyeres.2017.08.004","article-title":"The mechanism of cone cell death in Retinitis Pigmentosa","volume":"62","author":"Campochiaro","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.freeradbiomed.2023.01.021","article-title":"Reduced Inspired Oxygen Decreases Retinal Superoxide Radicals and Promotes Cone Function and Survival in a Model of Retinitis Pigmentosa","volume":"198","author":"Kanan","year":"2023","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/glia.23016","article-title":"Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa","volume":"64","author":"Zabel","year":"2016","journal-title":"Glia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1167\/iovs.61.14.36","article-title":"Spectrum of disease severity in patients with X-linked retinitis pigmentosa due to RPGR mutations","volume":"61","author":"Karali","year":"2020","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fahim, A.T., Bowne, S.J., Sullivan, L.S., Webb, K.D., Williams, J.T., Wheaton, D.K., Birch, D.G., Daiger, S.P., and Janecke, A.R. (2011). Allelic heterogeneity and genetic modifier loci contribute to clinical variation in males with X-linked retinitis pigmentosa due to rpgr mutations. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023021"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dvoriantchikova, G., Lypka, K.R., and Ivanov, D. (2022). The Potential Role of Epigenetic Mechanisms in the Development of Retinitis Pigmentosa and Related Photoreceptor Dystrophies. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.827274"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.61.10.1","article-title":"Gradual increase in environmental light intensity induces oxidative stress and inflammation and accelerates retinal neurodegeneration","volume":"61","author":"Kutsyr","year":"2020","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1016\/j.ymthe.2024.10.017","article-title":"Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review","volume":"32","author":"Wang","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Xue","year":"2020","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.64.7.39","article-title":"Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions","volume":"64","author":"Drag","year":"2023","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100915","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors\u2013Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/hmg\/ddae144","article-title":"Delivering large genes using adeno-associated virus and the CRE-lox DNA recombination system","volume":"33","author":"Datta","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/hum.2019.220","article-title":"Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?","volume":"31","author":"Tornabene","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ahmad, I. (2022). CRISPR\/Cas9\u2014A Promising Therapeutic Tool to Cure Blindness: Current Scenario and Future Prospects. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911482"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-biochem-060815-014607","article-title":"CRISPR\/Cas9 in Genome Editing and beyond","volume":"85","author":"Wang","year":"2016","journal-title":"Annu. Rev. Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene Editing for CEP290 -Associated Retinal Degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/iovs.61.4.31","article-title":"In vivo CRISPR\/Cas9-mediated genome editing mitigates photoreceptor degeneration in a mouse model of X-linked retinitis pigmentosa","volume":"61","author":"Hu","year":"2020","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","article-title":"CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool","volume":"431","author":"Brokowski","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2020.1804853","article-title":"Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases","volume":"29","author":"Xue","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Grainok, J., Pitout, I.L., Chen, F.K., McLenachan, S., Jeffery, R.C.H., Mitrpant, C., and Fletcher, S. (2024). A Precision Therapy Approach for Retinitis Pigmentosa 11 Using Splice-Switching Antisense Oligonucleotides to Restore the Open Reading Frame of PRPF31. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063391"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1038\/mtna.2016.89","article-title":"Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation","volume":"5","author":"Slijkerman","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bph.12330","article-title":"Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy","volume":"170","author":"Loma","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/519025","article-title":"RNA Interference\u2013mediated suppression and replacement of human rhodopsin in vivo","volume":"81","author":"Palfi","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101089","DOI":"10.1016\/j.preteyeres.2022.101089","article-title":"Optogenetics for visual restoration: From proof of principle to translational challenges","volume":"91","author":"Lindner","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_45","first-page":"4623","article-title":"Physiology 2021 symposium \u2019Photoreceptors in Health and Monogenic Disease","volume":"600","author":"Moore","year":"2022","journal-title":"J. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy","volume":"27","author":"Sahel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1167\/tvst.13.10.25","article-title":"Multi-Characteristic Opsin Therapy to Functionalize Retina, Attenuate Retinal Degeneration, and Restore Vision in Mouse Models of Retinitis Pigmentosa","volume":"13","author":"Batabyal","year":"2024","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/j.ymthe.2023.06.012","article-title":"Successful large gene augmentation of USH2A with non-viral episomal vectors","volume":"31","author":"Toms","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/emmm.201302948","article-title":"Effective delivery of large genes to the retina by dual AAV vectors","volume":"6","author":"Trapani","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-4939-9139-6_14","article-title":"SubILM injection of AAV for gene delivery to the retina","volume":"Volume 1950","author":"Gamlin","year":"2019","journal-title":"Methods in Molecular Biology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation\u2013Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_53","unstructured":"Adam, M.P., Feldman, J., and Mirzaa, G.M. (1993). RPE65-Related Leber Congenital Amaurosis\/Early-Onset Severe Retinal Dystrophy. GeneReviews, University of Washington."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Nguyen, X.-T., Moekotte, L., Plomp, A.S., Bergen, A.A., van Genderen, M.M., and Boon, C.J.F. (2023). Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087481"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jop.2018.0087","article-title":"Gene Therapy for Inherited Retinal Degeneration","volume":"35","author":"Arbabi","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Fenner, B.J., Tan, T.-E., Barathi, A.V., Tun, S.B.B., Yeo, S.W., Tsai, A.S.H., Lee, S.Y., Cheung, C.M.G., Chan, C.M., and Mehta, J.S. (2022). Gene-Based Therapeutics for Inherited Retinal Diseases. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.794805"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ito, N., Miura, G., Shiko, Y., Kawasaki, Y., Baba, T., Yamamoto, S., and Nakazawa, M. (2022). Progression Rate of Visual Function and Affecting Factors at Different Stages of Retinitis Pigmentosa. BioMed Res. Int., 2022.","DOI":"10.1155\/2022\/7204954"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ymthe.2020.11.029","article-title":"Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy","volume":"29","author":"Maguire","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_59","first-page":"122","article-title":"Phase 1\/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa","volume":"267","author":"Michaelides","year":"2024","journal-title":"Arch. Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41434-021-00258-6","article-title":"Restoration of RPGR expression in vivo using CRISPR\/Cas9 gene editing","volume":"29","author":"Gumerson","year":"2021","journal-title":"Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12967-024-04911-7","article-title":"The mechanistic functional landscape of retinitis pigmentosa: A machine learning-driven approach to therapeutic target discovery","volume":"22","author":"Loucera","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMra2204787","article-title":"Artificial Intelligence in Molecular Medicine","volume":"388","author":"Gomes","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1136\/bjophthalmol-2020-318544","article-title":"Prediction of causative genes in inherited retinal disorder from fundus photography and autofluorescence imaging using deep learning techniques","volume":"105","author":"Ninomiya","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.survophthal.2024.11.007","article-title":"Applications of artificial intelligence to inherited retinal diseases: A systematic review","volume":"70","author":"Issa","year":"2024","journal-title":"Surv. Ophthalmol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wu, K.Y., Mina, M., Sahyoun, J.-Y., Kalevar, A., and Tran, S.D. (2023). Retinal Prostheses: Engineering and Clinical Perspectives for Vision Restoration. Sensors, 23.","DOI":"10.3390\/s23135782"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2015.04.032","article-title":"Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind","volume":"122","author":"Ho","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41419-020-02955-3","article-title":"Stem\/progenitor cell-based transplantation for retinal degeneration: A review of clinical trials","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13287-023-03526-x","article-title":"Stem cell therapy for inherited retinal diseases: A systematic review and meta-analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Stem Cell Res. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13287-017-0661-8","article-title":"Long-Term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients","volume":"8","author":"Liu","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e13392","DOI":"10.15252\/emmm.202013392","article-title":"Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders","volume":"13","author":"Pavlou","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.66.1.6","article-title":"A Penetrable AAV2 Capsid Variant for Efficient Intravitreal Gene Delivery to the Retina","volume":"66","author":"He","year":"2025","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Vald\u00e9s-S\u00e1nchez, L., Borrego-Gonz\u00e1lez, S., Montero-S\u00e1nchez, A., Massalini, S., de la Cerda, B., D\u00edaz-Cuenca, A., and D\u00edaz-Corrales, F.J. (2022). Mesoporous Silica-Based Nanoparticles as Non-Viral Gene Delivery Platform for Treating Retinitis Pigmentosa. J. Clin. Med., 11.","DOI":"10.3390\/jcm11082170"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41565-020-0696-3","article-title":"Subretinally injected semiconducting polymer nanoparticles rescue vision in a rat model of retinal dystrophy","volume":"15","author":"Manfredi","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1038\/s41467-022-31368-3","article-title":"Light-induced charge generation in polymeric nanoparticles restores vision in advanced-stage retinitis pigmentosa rats","volume":"13","author":"Francia","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene Therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ajhg.2017.06.012","article-title":"Human Germline Genome Editing","volume":"101","author":"Ormond","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Malvasi, M., Casillo, L., Avogaro, F., Abbouda, A., and Vingolo, E.M. (2023). Gene Therapy in Hereditary Retinal Dystrophies: The Usefulness of Diagnostic Tools in Candidate Patient Selections. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813756"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Liu, Y., Zong, X., Cao, W., Zhang, W., Zhang, N., and Yang, N. (2024). Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress. Biomolecules, 14.","DOI":"10.3390\/biom14080903"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1179\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:13Z","timestamp":1760032873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":78,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["medicina61071179"],"URL":"https:\/\/doi.org\/10.3390\/medicina61071179","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,29]]}}}